{
    "organizations": [],
    "uuid": "23e7e047bb5c906c8f78c201795d0de185d0cc5e",
    "author": "",
    "url": "https://www.reuters.com/article/brief-fda-to-review-dupixent-as-potentia/brief-fda-to-review-dupixent-as-potential-treatment-for-moderate-to-severe-asthma-idUSFWN1QJ1GD",
    "ord_in_thread": 0,
    "title": "BRIEF-FDA To Review Dupixent® (Dupilumab) As Potential Treatment For Moderate-To-Severe Asthma",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 2, 2018 / 10:38 AM / in 9 minutes BRIEF-FDA To Review Dupixent® (Dupilumab) As Potential Treatment For Moderate-To-Severe Asthma Reuters Staff March 2 (Reuters) - Regeneron Pharmaceuticals Inc: * FDA TO REVIEW DUPIXENT® (DUPILUMAB) AS POTENTIAL TREATMENT FOR MODERATE-TO-SEVERE ASTHMA * ‍PER PRESCRIPTION DRUG USER FEE ACT, TARGET ACTION DATE IS OCTOBER 20, 2018​ * ‍POTENTIAL USE OF DUPIXENT IN ASTHMA IS CURRENTLY UNDER CLINICAL DEVELOPMENT​ * SAFETY AND EFFICACY FOR ‍DUPIXENT IN ASTHMA HAVE NOT BEEN FULLY EVALUATED BY ANY REGULATORY AUTHORITY​ Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)",
    "published": "2018-03-02T12:37:00.000+02:00",
    "crawled": "2018-03-02T13:01:44.052+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "minute",
        "review",
        "dupilumab",
        "potential",
        "treatment",
        "asthma",
        "reuters",
        "staff",
        "march",
        "reuters",
        "regeneron",
        "pharmaceutical",
        "inc",
        "fda",
        "review",
        "dupilumab",
        "potential",
        "treatment",
        "asthma",
        "prescription",
        "drug",
        "user",
        "fee",
        "act",
        "target",
        "action",
        "date",
        "october",
        "use",
        "dupixent",
        "asthma",
        "currently",
        "clinical",
        "safety",
        "efficacy",
        "asthma",
        "fully",
        "evaluated",
        "regulatory",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}